4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 99 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $502,800 | -3.4% | 39,481 | +37.0% | 0.00% | 0.0% |
| Q2 2023 | $520,334 | +5.0% | 28,814 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $495,656 | -48.5% | 28,814 | -31.7% | 0.00% | 0.0% |
| Q4 2022 | $961,569 | +105.5% | 42,185 | -27.6% | 0.00% | 0.0% |
| Q3 2022 | $468,000 | +31.5% | 58,256 | +14.0% | 0.00% | 0.0% |
| Q2 2022 | $356,000 | -12.3% | 51,108 | +90.2% | 0.00% | 0.0% |
| Q1 2022 | $406,000 | +50.4% | 26,872 | +118.1% | 0.00% | +100.0% |
| Q4 2021 | $270,000 | -14.0% | 12,320 | +5.8% | 0.00% | 0.0% |
| Q3 2021 | $314,000 | +24.1% | 11,648 | +11.0% | 0.00% | 0.0% |
| Q2 2021 | $253,000 | -44.4% | 10,495 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $455,000 | +4.6% | 10,495 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $435,000 | – | 10,495 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |